Millendo starts Phase II trial of ATR-101 to treat CAH

US-based Millendo Therapeutics has commenced the multicentre, single-blind, multiple dose Phase II clinical trial of its new oral drug candidate, ATR-101, to treat classic congenital adrenal hyperplasia (CAH).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news